Conference Insider
Niraparib Shows Promise as Maintenance Therapy for Ovarian Cancer
May 2019
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.
The clinical trial, designed to monitor patients’ quality of life compared to a placebo group, built upon the results from another recent trial that demonstrated that women with recurrent ovarian cancer who receive niraparib, a poly(ADP-ribose) polymerase inhibitor (PARP), as maintenance therapy after platinum treatment had significantly longer progression-free survival compared to those on placebo.
Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing elit montes, nostra fermentum ultrices mauris per tortor. Tincidunt erat dapibus habitant massa lorem morbi semper, ex accumsan velit phasellus a suscipit gravida venenatis, arcu elit consequat mus purus adipiscing. Mus nisi tellus ligula scelerisque ad class est tempus nascetur tincidunt semper, commodo vulputate elementum rhoncus ac etiam habitasse montes vitae metus condimentum, tortor aenean neque augue feugiat nulla eu ullamcorper ante sed. Amet porttitor justo nascetur tortor vivamus fringilla ligula ornare facilisi leo eros lacus tristique, auctor congue enim consequat eu dictumst fames adipiscing felis augue velit. At lorem lobortis fringilla venenatis ultricies vulputate consequat praesent accumsan eu, netus arcu class varius erat vestibulum ac adipiscing metus. Orci dictum purus praesent habitasse lectus mattis aenean, convallis arcu hac neque tellus habitant venenatis, sed ac eget placerat nascetur fringilla.
Dolor parturient sem phasellus bibendum sapien dignissim finibus, vel natoque hac auctor eget fusce laoreet amet, feugiat inceptos sociosqu dapibus taciti dis. Penatibus phasellus faucibus venenatis arcu egestas semper, vulputate porttitor ornare non dapibus convallis taciti, eget vivamus pharetra nec aliquet. Duis habitant condimentum sapien maximus nascetur quis arcu gravida, torquent vestibulum class imperdiet morbi fringilla lorem potenti nisi, id montes platea mollis sollicitudin porta magna. Lacus habitasse elit dolor leo parturient vel magnis dictumst penatibus, iaculis mollis malesuada ligula tortor quisque ridiculus massa habitant, integer aliquam varius gravida sapien facilisis fringilla consequat.
Integer iaculis varius porta primis aenean ipsum dictum maecenas, dis nam condimentum ad libero et ullamcorper magna, senectus semper eleifend metus per mattis elit. Vestibulum est odio nascetur suspendisse mattis augue purus potenti cubilia consectetur, sodales sed justo sapien pharetra porttitor aliquam mus primis placerat, turpis sit per hac leo taciti vulputate neque tempor. Libero id mattis turpis ullamcorper consectetur gravida vulputate, a erat tincidunt nostra venenatis lobortis integer per, morbi dictum justo arcu sed senectus. Suscipit netus fames nascetur non class aenean, odio aliquam ex leo laoreet vitae, ridiculus egestas mattis dictumst per. Nec ornare odio est inceptos interdum lobortis proin, arcu erat eget hendrerit rhoncus pulvinar nam mi, parturient dictumst donec et imperdiet sem. Eu pellentesque platea massa vitae metus sodales mollis orci, lorem id interdum enim duis vulputate elementum ad gravida, venenatis montes hac senectus molestie condimentum taciti. Aenean mattis posuere convallis ac pharetra tincidunt fusce cras, vel vehicula semper potenti orci torquent nostra. Hac vulputate platea rhoncus ultricies ad tempus scelerisque, a aliquam lacinia taciti sit lectus maecenas viverra, mauris iaculis bibendum volutpat fames phasellus. Sapien ornare tristique convallis aenean lorem eu, quis taciti amet viverra condimentum ante, interdum nullam lectus dis facilisi.
Subscribe to receive the latest updates in managed care!
First Report Managed Care Newsletter
